Open AccessOutstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn
Author(s) -
Muhammad Wasif Saif
Publication year - 2020
Publication title -
pancreas
Language(s) - English
Resource type - Journals
ISSN - 2471-142X
DOI - 10.17140/poj-4-e012
Subject(s) - folfirinox , irinotecan , gemcitabine , pancreatic cancer , oxaliplatin , medicine , oncology , cancer , fluorouracil , colorectal cancer
The American Cancer Society’s estimates that 57,600 people (30,400 men and 27,200 women) will be diagnosed with pancreatic cancer in the United States for 2020 and approximately 47,050 people (24,640 men and 22,410 women) will die of pancreatic cancer in 2020.1 Despite advances in first-line therapy such as gemcitabine/nab-paclitaxel and fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) in advanced pancreatic cancer (aPC), median overall survival remains less than 12-months.2